Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND ...
Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Medscape

Drop in HIV/HCV Coinfections After Nationwide HCV Program

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Urban Milwaukee

HACM Completes Section 8 Housing Choice Voucher Waiting List Lottery

MILWAUKEE — The Housing Authority of the City of Milwaukee (HACM) has completed a random lottery to establish its official ...